LYON, France , Feb. 1, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the submission of its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) on January 31, 2013 for the Company's Ablatherm-HIFU (

Record full year revenue of approximately EUR 26.0 million ( USD 33.5 million ), up 16.5% year-over-year Record fourth quarter total revenue of approximately EUR 9.4 million ( USD 12.2 million ), up 25% year-over-year Record lithotripsy sales with 21 devices sold in fourth quarter and 52 devices

Recent Highlights Recorded robust 13% sales growth over the nine-month period Strong lithotripsy sales in third quarter and replenished fourth quarter device backlog in lithotripsy and Ablatherm-HIFU Generated positive cash flow during third quarter 2012 Held productive pre-PMA meeting with U.S.

LYON, France , Nov. 7, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its third quarter 2012 results announcement, which will take place on Wednesday, November 21, 2012 , before the opening of the market.

Expanding Interest for HIFU Use in Treating Prostate and Liver Cancer

Strengthens Sales Team In Line With Strategy to Focus on U.S. Urology Market

Second Quarter 2012 Highlights Revenues increased 61% year-over-year to EUR 6.1 million ( USD 7.8 million ) Strong lithotripsy sales with fourteen devices sold globally Strengthened third quarter device backlog to sixteen lithotripsy devices at the end of August 2012 Completed U.S.

Strengthens Team for Final Stages of Ablatherm-HIFU Phase II/III Clinical Trial for Prostate Cancer

LYON, France , Aug. 17, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today provided an update regarding its Ablatherm-HIFU ( High Intensity Focused Ultrasound ) ENLIGHT U.S. clinical trial for the indication of low risk, localized prostate cancer.

LYON, France , Aug. 3, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its second quarter 2012 results announcement, which will take place on Thursday, August 30, 2012 , before the opening of the market.